Refine by
Blood Count Articles & Analysis
20 news found
Currently, patients with MDS are monitored with blood tests to measure complete blood cell counts and bone marrow analyses to detect the appearance of leukemic blasts heralding the development of AML. However, blood tests have a very low sensitivity to detect rare blasts and bone marrow tests involve an invasive procedure that ...
Chemotherapy drugs may reduce patients’ platelet and white blood cell counts and weaken their immune systems. This leaves them more vulnerable to wound infections. ...
JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. ...
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...
Utilizing a patented, disposable cartridge preloaded with all necessary reagents, HemoScreen reduces reagent waste and eliminates the need for routine maintenance. With just one drop of blood, HemoScreen provides Complete Blood Count (CBC) results with 20 standard parameters, as well as comprehensive abnormal cell flagging for earlier detection ...
Drowsiness and mental instability. Blood emesis. Malfunction in the kidney. Extreme lethargy and tiredness. Low count of haemoglobin and other blood cells. Abnormal bleeding even in the minor wounds. ...
Utilizing a patented, disposable cartridge preloaded with all necessary reagents, HemoScreen reduces reagent waste and eliminates the need for routine maintenance. With just one drop of blood, HemoScreen provides Complete Blood Count (CBC) results with 20 standard parameters, as well as comprehensive abnormal cell flagging for earlier detection ...
PixCell Medical's flagship product, HemoScreen™, is a point-of-care blood testing platform that can conduct blood cell analysis within five minutes by applying AI-driven novel microfluidic and lab-on-a-cartridge technology. FDA-cleared, CE-marked and TGA-approved, the HemoScreen reliably conducts five-part differential complete blood ...
HemoScreen™, developed by PixCell Medical, is the only 5-part differential Complete Blood Count (CBC) analyzer that is both FDA-cleared and CE-marked for point-of-care use. ...
Since its founding in 1968, Sysmex has developed its business by focusing on the hematology field (blood cell count tests), which analyzes the number, type, and size of red and white blood cells as well as platelets. Sysmex has adopted a modular concept since the launch of the XN-Series Automated Hematology Analyzer (“XN-Series”) in ...
RURAL plans to deploy HemoScreen hematology analyzers within the MEU lab to do phenotypic measurements in a non-clinical research setting in the rural south, and to test the performance characteristics of the HemoScreen in this setting. The blood count data collected will be analyzed as part of the broader study to better understand risk and resilience factors ...
” PixCell Medical’s HemoScreen™ is the first and only FDA-cleared and CE-marked 5-part differential complete blood count (CBC) analyzer that is intended for use at the point of care. ...
“PixCell’s HemoScreen brings lab-quality haematology results closer to the patient, making it possible to analyze Complete Blood Count (CBC) with the five-part differential at a patient’s bedside, without the skills of a biomedical scientist, which is a prerequisite for traditional haematology,” said Johan Snis, Sales Manager of Triolab. ...
The paper, titled A Novel Approach to Hematology Testing at the Point-Of-Care, compares the traditional analysis methods used for blood cell counting to the new imaging flow cytometry method used by the HemoScreen. ...
"Almost 30% of Australians live in rural areas making access to many healthcare services difficult. To take a simple blood test, one may have to travel hours to the nearest city or have blood samples flown out to a lab, causing significant delays in receiving results. This technology makes the most common complete blood count ...
Israeli blood testing startup S.D. Sight Diagnostics Ltd. has raised $71 million from international venture capital funds and U.S. corporations, Clal Biotechnology Industries Ltd. revealed in a report sent to the Tel Aviv Stock Exchange last week. ...
Of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, a decrease in neutrophil count was reported in 30% of patients and 16% had Grade 3 or 4 events. ...
This requires flying out blood samples or driving several hours to bring samples to a lab that may be located hundreds of miles away,” said Dr. ...
“It’s been sixty years since the last immunological benchmarks (Complete Blood Counts) were introduced into general medical practice. This much more sophisticated method reflects the tremendous explosion of knowledge generated in the field.” The researchers developed their unique data by following a group of healthy volunteers (135) for nine ...
With HORIBA Medical’s proven technologies and innovation, the Yumizen H500 is a compact and robust hematology analyzer tailored for all types of laboratories and other clinical settings demanding easy operation and reliable analysis such as routine and satellite laboratories, Emergency Care and Physician’s Offices Based on a unique 3-reagent system with low consumption, the Yumizen ...